MedTrace Logo

Neonatal Hyperbilirubinaemia in the Democratic Republic of Congo

NCT03880591 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 306

Last updated 2020-12-14

No results posted yet for this study

Summary

Neonatal hyperbilirubinaemia (NH) is common among healthy neonates and normally resolves within a week. Untreated pathological hyperbilirubinaemia, however, can result in long-term neurological sequelae, which compromise childhood development, or may result in perinatal death. True population-based data from middle to low-income countries are scarce and NH contribution to morbidity and mortality remains unclear. With this study the investigators aim at assessing the prevalence of neonatal hyperbilirubinaemia in a cohort of newborns in a maternity hospital in Kinshasa, the Democratic Republic of Congo, and at evaluating the possible risk factors for NH in the mother and the baby.

Conditions

  • Neonatal Hyperbilirubinemia

Sponsors & Collaborators

  • Kinshasa School of Public Health

    collaborator OTHER

  • University of Oxford

    lead OTHER

Principal Investigators

  • Caterina Fanello · University of Oxford

Eligibility

Max Age
60 Minutes
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-03-07
Primary Completion
2020-12-03
Completion
2020-12-10

Countries

  • Democratic Republic of the Congo

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03880591 on ClinicalTrials.gov